

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RemeGen Co., Ltd.*

榮昌生物製藥(煙台)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

ANNOUNCEMENT UNUSUAL MOVEMENT IN TRADING OF SHARES

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

IMPORTANT NOTICE:

- The closing prices of the A shares of RemeGen Co., Ltd.* (榮昌生物製藥(煙台)股份有限公司) (the “**Company**”) experienced a cumulative decline deviation of more than 30% over three consecutive trading days, namely July 8, 2024, July 9, 2024, and July 10, 2024. According to the relevant provisions of the Trading Rules of the Shanghai Stock Exchange (《上海證券交易所交易規則》) and the Rules on the Real-time Monitoring of Stock Abnormal Trading on the Shanghai Stock Exchange STAR Market (《上海證券交易所科創板股票異常交易實時監控細則》), this constitutes an abnormal fluctuation in stock trading.
- After having made self-investigation and made enquiries with the controlling shareholders and de facto controllers in writing, the Company confirms that, as of the date of this announcement, there are no material matters or information which are required to be disclosed but have not been disclosed.
- Investors should be aware of investment risks and are advised to make rational decisions and invest prudently.

I. PARTICULARS OF ABNORMAL FLUCTUATION IN STOCK TRADING

The closing prices of the A shares of the Company experienced a cumulative decline deviation of more than 30% over three consecutive trading days, namely July 8, 2024, July 9, 2024, and July 10, 2024. According to the relevant provisions of the Trading Rules of the Shanghai Stock Exchange and the Rules on the Real-time Monitoring of Stock Abnormal Trading on the Shanghai Stock Exchange STAR Market, this constitutes an abnormal fluctuation in stock trading.

II. RELEVANT INFORMATION THAT THE COMPANY PAYS ATTENTION TO AND HAS VERIFIED

In response to the abnormal fluctuations in the trading of its shares, the Company has verified the relevant matters, and the relevant information is set out below:

(I) Production and Business Operations

After having made self-investigation, the Company confirms that its current production and business operations are proceeding normally. There have been no significant adjustments to the market environment or industry policies, and there have been no substantial fluctuations in production costs or sales. The internal order of production and operation is stable. The Company is operating healthily, with revenue for the first quarter of 2024 reaching RMB330 million, representing a significant year-on-year increase of 96.41%, and indicating continuous growth in product sales. In terms of cash flow, the Company has made adequate preparations and obtained sufficient bank credit, ensuring the safety of its capital flow. The de facto controllers of the Company have full confidence in the future development prospect of the Company and intend to increase their shareholdings in the Company through Yantai Rongchang Holding Group Co., Ltd. (煙台榮昌控股集團有限公司), a company under their control. For details of this shareholding increase plan, please refer to the “Announcement of RemeGen Co., Ltd. Regarding the Shareholding Increase Plan by A Company Controlled by the De facto Controllers” (Announcement No. 2024-035) disclosed by the Company on the website of Shanghai Stock Exchange (www.sse.com.cn) on July 9, 2024.

(II) Significant Events

After self-investigation and verification through letters of confirmation from the controlling shareholders and de facto controllers of the Company, as of the date of this announcement, apart from the matters that have been disclosed by the Company, there are no significant events involving the controlling shareholders and de facto controllers of the Company that could lead to the abnormal fluctuations in the trading of the Company’s shares; and there is no other significant information of the Company which are required to be disclosed but have not been disclosed, including but not limited to major asset reorganizations, share issuances, major transaction-related matters, business reorganizations, share repurchases, equity incentives, bankruptcy reorganizations, major business collaborations, introduction of strategic investors, and other significant events.

(III) Media Reports, Market Rumors, and Hot Topics

Market rumors suggest that the progress of the Company’s external licensing of certain products is slower than expected. However, the outcome of the Company’s self-investigation reveals that all of its business operations are currently proceeding normally and no hot market topics are involved.

(IV) Other Price-sensitive Information

After verification, the Company has not found any other major events that may have a material impact on its share price, and the Company's directors, supervisors, senior management, controlling shareholders, and de facto controllers did not engage in any trading of the Company's shares during the period of abnormal fluctuations in trading of its shares.

III. STATEMENT OF THE BOARD OF DIRECTORS AND COMMITMENT FROM THE RELATED PARTIES

The Board of Directors of the Company confirms that except for the matters that have been disclosed in accordance with the relevant requirements, the Company does not have any event which are required to be disclosed but have not been disclosed pursuant to relevant rules including the Rules Governing the Listing of Stocks on the STAR Market of the Shanghai Stock Exchange (the "STAR Market Listing Rules") or any planning and intention relating to such events, nor is the Board of Directors aware of any information which are required to be disclosed but have not been disclosed pursuant to relevant rules including the STAR Market Listing Rules and may have a material impact on the trading prices of the shares of the Company and their derivatives.

IV. RELEVANT RISK WARNING

The Company solemnly reminds investors that Shanghai Securities News, China Securities Journal, Securities Times and Securities Daily are the designated newspapers of the Company for information disclosure, and the website of the Shanghai Stock Exchange (www.sse.com.cn) is the designated website of the Company for information disclosure. Information published on the aforementioned media shall prevail for all information of the Company. Investors are advised to make rational investments and pay attention to investment risks.

By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and executive Director

Yantai, the PRC
July 12, 2024

As at the date of this announcement, the Board of the Company comprises Mr. Wang Weidong, Dr. Fang Jianmin, Dr. He Ruyi and Mr. Lin Jian as the executive Directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive Directors, and Mr. Hao Xianjing, Dr. Ma Lan and Mr. Chen Yunjin as the independent non-executive Directors.

* For identification purposes only